RE:Then consider the comments here towards management You are spewing absolute garbage, and have no idea what you're talking about. Medipharm and VIVOs COMBINED OPEX is 10% lower than when Medipharm operated standalone. In your mind, reduced input costs from vertically integrating, improved plant utilization, new revenue streams (international & direct to patient) delayed profitability? Take a look at their margin improvements QoQ post acquisition. Yes, dilution sucks but in the current environment cash is king and using equity was a prudent decision. The VIVO deal laid the foundation for the company prosper. Management also aimed for positive EBITDA & cash flow in FIRST HALF 2024 which includes the current quarter, and we are trending in that direction. Senior management has executed on delivering tangible improvements to the business and should be commended.